Immunogenicity of sarilumab and impact on safety and efficacy in Japanese patients with rheumatoid arthritis: analysis of two Phase 3 randomised clinical trials
Yoshiya Tanaka(University of Occupational and Environmental Health Japan), Hideto Kameda(Toho University), Toshiya Takahashi(Tohoku University), Mariko Sumi(Sanofi (Japan)), Christine Xu(Sanofi (United States)), Owen Hagino, Naoto Kato(Jichi Medical University), Hubert van Hoogstraten(Sanofi (United States))
Cited by 5
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Efficacy of Paroxetine in the Treatment of Adolescent Major Depression: A Randomized, Controlled Trial
|Journal of the American Academy of Child & Adolescent Psychiatry|2001|648
Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis
|Annals of the Rheumatic Diseases|2007|413
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Respiratory Medicine|2021|248